GLEBioassay starts activities to develop a nanobiosensing platform for cancer immunotherapy monitoring

by Virginia Greco

The kick-off meeting of the GLEBioassay project, led by ICN2 group leader ICREA Prof. Arben Merkoçi, took place at the ICN2 on Wednesday 9 March. The project aims to develop a multiplexed point-of-care nanobiosensing platform to monitor the efficiency of naxitamab-based immunotherapy in neuroblastoma.

Representatives of the institutes that will carry out the GLEBioassay project over the next three years met at the ICN2 on March 9 to launch its scientific activities. Coordinated by the ICN2 Nanobioelectronics and Biosensors Group, led by ICREA Prof. Arben Merkoçi, the consortium includes the Private Foundation for Research and Teaching Sant Joan de Déu (FSJD, Spain), the company Nehir Biyoteknoloji (Turkey) and the Palacký University Olomouc (Czech Republic).

This project aims to develop a multiplexed nanobiosensing platform to monitor the efficiency of immunotherapy based on naxitamab –a monoclonal antibody— against neuroblastoma. This electrophoretical paper-based portable platform with electrochemical readout will enable point-of-care applications and has the potentiality to be used for controlling the effects of other immunotherapies.

This project is one of the 10 funded through the EuroNanoMed-III Joint Transnational call 2021 “European Innovative Research & Technological Development Projects in Nanomedicine”.

Photo (from left to right): Anna Puig, Enric Calucho, Dr Giulio Rosati, Dr Carlos Javier Rodríguez (Private Foundation for Research and Teaching Sant Joan de Déu - FSJD), Gabriel Maroli, Dr Marianna Rossetti, Prof. Michal Otyepka (Palacký University Olomouc -UP), Prof. Arben Merkoçi, Dr. Gustavo Dalkiranis, Dr Ruslan Álvarez.